An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone started taking a peptide called MOTS‑c and, within a week, noticed several sudden nosebleeds — four in the shower and one while playing tennis. They hadn’t changed anything else in their routine and wondered if the peptide could be the cause. This is an anecdote: a single person reporting events, not a controlled study. MOTS‑c is a short protein-like molecule (a peptide) that was originally found inside cells and has been studied for effects on metabolism and energy use. It’s not a household medicine like Ozempic. Research so far is mostly early-stage — done in cells or animals, with only limited data in people. In plain terms, it’s a biological compound people are experimenting with for things like energy and metabolic health, but it isn’t an established, widely approved drug. What we actually have here is a personal report — one person linking new nosebleeds to starting MOTS‑c. That kind of story can raise a flag, but it doesn’t prove the peptide caused the bleeds. Nosebleeds are common and can happen for many reasons: dry air, nose picking, allergies, infections, high blood pressure, certain medications (like blood thinners), or local irritation. The report doesn’t include blood pressure readings, other medical conditions, or lab tests. There’s no mention of a controlled trial, no comparison group, and no systematic monitoring, so the evidence is weak and suggestive at best. Why this matters is straightforward. If a supplement or experimental peptide can increase bleeding risk, that’s important for anyone considering using it, especially people with known bleeding disorders, those on anticoagulant (blood-thinning) drugs, or people with high blood pressure. Even for generally healthy people, unexpected nosebleeds can be alarming and can signal something that needs a doctor’s check. A single report like this is enough reason to pause, monitor closely, and talk to a healthcare professional rather than assume it’s harmless. There are important caveats. Anecdotes don’t establish cause and effect. MOTS‑c’s safety profile in humans is not well established in the public scientific literature, and it is not an approved treatment with standardized dosing and oversight. Possible risks include unknown interactions with other medications or underlying conditions. If someone experiences new or frequent nosebleeds after starting any new compound, they should stop it and seek medical advice. Only controlled clinical studies can tell us whether MOTS‑c really raises bleeding risk. Bottom line: an individual reported nosebleeds after starting MOTS‑c, which is a red flag worth medical follow‑up but not proof of causation; more careful studies are needed.
Source: r/Peptides